{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-02-27", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnswerDate=2018-02-27", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-02-27&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnswerDate=2018-02-27", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-02-27", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-02-27", "items" : [{"_about" : "http://data.parliament.uk/resources/847760", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/847760/answer", "answerText" : {"_value" : "
Intellectual property protections apply to designs replicated by 3D printing in the same way as they apply to articles created by more traditional manufacturing processes. The protection and enforcement measures available will vary according to what rights exist in the design, and the circumstances of each case, but these could include both civil and criminal sanctions. Relevant protections could include copyright, registered and unregistered design rights, patents or trade marks.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3980", "label" : {"_value" : "Biography information for Mr Sam Gyimah"} } , "answeringMemberConstituency" : {"_value" : "East Surrey"} , "answeringMemberPrinted" : {"_value" : "Mr Sam Gyimah"} , "dateOfAnswer" : {"_value" : "2018-03-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-03-02T10:12:11.93Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Intellectual Property: 3D Printing"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what intellectual property protections and enforcement measures counterfeiting authorities may use for counterfeiting and piracy of designs made by 3D printing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4676", "label" : {"_value" : "Biography information for Marsha De Cordova"} } , "tablingMemberConstituency" : {"_value" : "Battersea"} , "tablingMemberPrinted" : [{"_value" : "Marsha De Cordova"} ], "uin" : "129436"} , {"_about" : "http://data.parliament.uk/resources/850360", "AnsweringBody" : [{"_value" : "HM Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/850360/answer", "answerText" : {"_value" : "
The deficit has been reduced by three quarters from its post-war peak in 2010, from 9.9% GDP to 2.3% GDP last year.<\/p>
<\/p>
The OBR\u2019s November forecasts shows the deficit reducing further, to 1.1% of GDP in 2022-23.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3935", "label" : {"_value" : "Biography information for Mel Stride"} } , "answeringMemberConstituency" : {"_value" : "Central Devon"} , "answeringMemberPrinted" : {"_value" : "Mel Stride"} , "dateOfAnswer" : {"_value" : "2018-02-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-02-27T15:54:56.917Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "CaTreasury"} , "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Public Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "What progress is being made on reducing the deficit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/474", "label" : {"_value" : "Biography information for Mr Nigel Evans"} } , "tablingMemberConstituency" : {"_value" : "Ribble Valley"} , "tablingMemberPrinted" : [{"_value" : "Mr Nigel Evans"} ], "uin" : "904046"} , {"_about" : "http://data.parliament.uk/resources/847708", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/847708/answer", "answerText" : {"_value" : "
Schools are responsible for ensuring that all staff, including supply staff, are aware of their safeguarding responsibilities. \u2018Keeping Children Safe in Education\u2019 statutory safeguarding guidance makes clear that all staff should read \u2018Part One - Safeguarding information for all staff at induction\u2019. It also requests that governing bodies/proprietors ensure that mechanisms are in place to support staff to understand and discharge their role and responsibilities as set out in Part One. The guidance states that all staff should receive safeguarding and child protection training at induction.<\/p>
<\/p>
Before placing a member of staff a supply agency must request sufficient information, including the experience, references, training, and qualifications the school needs for the post or that are required by law.<\/p>
<\/p>
To help schools achieve best value when using supply agencies the Department is working with the Crown Commercial Service to develop a commercial framework for agency supply teachers. Together with other requirements the framework will ensure that agencies adhere to standard levels of practice. The framework is expected to be available for schools to use from September 2018.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/111", "label" : {"_value" : "Biography information for Nick Gibb"} } , "answeringMemberConstituency" : {"_value" : "Bognor Regis and Littlehampton"} , "answeringMemberPrinted" : {"_value" : "Nick Gibb"} , "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-03-05T17:04:09.023Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Supply Teachers: Training"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Education, what assessment he has made of the (a) adequacy and (b) extent of the provision of safeguarding training provided by supply teacher agencies in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/534", "label" : {"_value" : "Biography information for Chris Ruane"} } , "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"} , "tablingMemberPrinted" : [{"_value" : "Chris Ruane"} ], "uin" : "129384"} , {"_about" : "http://data.parliament.uk/resources/847710", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/847710/answer", "answerText" : {"_value" : "
NHS England does not have any current plans to assess the coding of National Health Service care for patients with Mast Cell Activation Syndrome.<\/p>
<\/p>
In response to the commitments outlined in the UK Strategy for Rare Diseases, NHS England published the Rare Diseases Implementation Plan in which it proposed to monitor the development of International Classification of Diseases (ICD)-11 and support the accurate characterisation of patients through Human Phenotype Ontology terms as being developed through the 100,000 Genomes Project.<\/p>
<\/p>
More information about the NHS England Rare Diseases Implementation Plan can be found here:<\/p>
<\/p>
https://www.england.nhs.uk/publication/implementation-plan-for-the-uk-strategy-for-rare-diseases/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-05T15:41:57.293Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mast Cell Activation Syndrome"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of the coding of diagnoses of Mast Cell Activation Syndrome on NHS systems.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "129386"}
, {"_about" : "http://data.parliament.uk/resources/847711", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847711/answer", "answerText" : {"_value" : " Care for patients with Mast Cell Activation Syndrome (MCAS) in an outpatient setting will typically be within local allergy clinics, available in most hospitals. These services are commissioned locally by clinical commissioning groups. There are no current plans to designate or commission the care of patients with MCAS as a prescribed national specialised clinic or service.<\/p> <\/p> A list of local allergy clinics can be obtained from the British Society for Allergy and Clinical Immunology at:<\/p> <\/p> http://www.bsaci.org/professionals/allergy-specialists<\/a><\/p> <\/p> The Royal College of Physician\u2019s Improving Quality in Allergy Services scheme at:<\/p> <\/p>